Show simple item record

dc.contributor.authorDe Vita, Ferdinando
dc.contributor.authorChao, Joseph
dc.contributor.authorFuchs, Charles S.
dc.contributor.authorShitara, Kohei
dc.contributor.authorTabernero, Josep
dc.contributor.authorMuro, Kei
dc.contributor.authorVan Cutsem, Eric
dc.contributor.authorBang, Yung-Jue
dc.contributor.authorLanders, Gregory
dc.contributor.authorYen, Chia-Jui
dc.contributor.authorChau, Ian
dc.contributor.authorElme, Anneli
dc.contributor.authorLee, Jeeyun
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorCatenacci, Daniel
dc.contributor.authorYoon, Harry H.
dc.contributor.authorChen, Erluo
dc.contributor.authorAdelberg, David
dc.contributor.authorShih, Chie-Schin
dc.contributor.authorShah, Sukrut
dc.contributor.authorBhagia, Pooja
dc.contributor.authorWainberg, Zev A.
dc.date.accessioned2021-12-10T11:38:31Z
dc.date.available2021-12-10T11:38:31Z
dc.identifier.citationChao J., Fuchs C. S. , Shitara K., Tabernero J., Muro K., Van Cutsem E., Bang Y., De Vita F., Landers G., Yen C., et al., "Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials", JAMA ONCOLOGY, 2021
dc.identifier.issn2374-2437
dc.identifier.otherav_8b88334a-cd5d-4082-8a09-de3b691ef4ee
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/172322
dc.identifier.urihttps://doi.org/10.1001/jamaoncol.2021.0275
dc.description.abstractIMPORTANCE Immunotherapy has been associated with improved outcomes among patients who have received previous treatment for microsatellite instability-high (MSI-H) tumors.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.titleAssessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
dc.typeMakale
dc.relation.journalJAMA ONCOLOGY
dc.contributor.departmentCity of Hope , ,
dc.contributor.firstauthorID2622251


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record